There are several vaccines available in the market these days that help improve your immunity against the highly infectious disease Covid-19. But most of them are given via the intramuscular route into the deltoid or via injection. But researchers are now working on a new vaccine that you can simply swallow.
According to a report, the oral vaccine QYNDR – pronounced as ‘kinder’ – has completed its phase 1 clinical trial. The report by CNET suggests that QYNDR is awaiting some more funding to conduct more detailed and advanced trials.
The report said that it is pronounced as ‘kinder’ because it is much easier to deliver.
However, there are several challenges before it gets all the necessary approvals and is made available for the common man. Kyle Flanigan, the founder of QYNDR’s maker, US Specialty Formulations, said that it is really challenging to develop a vaccine that can survive making it through your digestive system.
“We have been able to figure out how to get a vaccine past the stomach and into the gut and have an appropriate response,” Flanigan said.
But they are now waiting for funding in order to take it to the additional clinical trials so that the vaccine can be finally taken to the market. Flanigan was recently in San Francisco to take part in the JP Morgan Healthcare Conference. He is trying to get more funding for the vaccine.
While there are several big names providing Covid-19 vaccines, researchers around the world are also working on developing new mucosal vaccines. However, they too are waiting for more data to confirm how efficient these vaccines are in stopping the infection from coronavirus. The research is important as Covid-19, despite being much less severe these days, is still here.
Meanwhile, Bharat Biotech has announced that it will launch its intranasal vaccine iNCOVACC this month. According to Krishna Ella, CMD of Bharat Biotech, the vaccine will be launched on Republic Day i.e. January 26.